Infectious Diseases
COVID-19 Prevention
Vaccination and Postexposure Prophylaxis: COVID-19 Prevention in Practice
COVID-19 continues to circulate and cause serious illness, even as immunity from vaccination and prior infection has changed the shape of that risk. COVID-19 vaccines and a newly US Food and Drug Administration (FDA)–approved postexposure antiviral therapy can work together, with one lowering the odds of infection and risk of severe disease and the other offering a preventive treatment option after a known exposure.
COVID-19 is not gone. SARS-CoV-2, the virus that causes it, continues to circulate in the United States, typically surging during the late summer and winter months. In January 2026, almost 1 of 100 deaths in the United States were from COVID-19. Compounding this sad statistic is the health care and economic burdens of COVID-19, including hospitalizations, clinic visits, and missed days of work and school. So, as much as we would like COVID-19 to be in our rearview mirror, unfortunately, it continues to be something that we must continue to consider as we move forward.
Fortunately, we have effective medical and nonmedical strategies available for the prevention and response to COVID-19. Some practical ways people can avoid the virus include using a mask in crowded indoor spaces during COVID-19 surges. People can also stay home when they suspect or know that they have been infected to avoid transmitting the virus to others. However, the most important way to prevent the spread and impact of COVID-19 is vaccination.
COVID-19 vaccines are safe and they work. Protection against infection is usually strongest in the weeks after vaccination, but their ability to prevent severe disease persists. Along with the immunity developed from prior infection, vaccines have dramatically reduced the risk of getting very sick with COVID-19. So, while some people still end up in the hospital and/or even die due to COVID-19, the numbers are nothing like what they were during the earlier years of the COVID-19 pandemic.
The basis of these vaccines has remained largely unchanged but has been tweaked to better respond to the SARS-CoV-2 variants that have evolved as the virus moves through the population. However, even the updated COVID-19 vaccines do not act as a force field that prevents infection altogether, and protection wanes as variants evade some of that immunity. Moreover, not everyone responds to vaccines the same way; people’s immune systems differ as much as their faces do. For example, older age and being on medication that can reduce one’s ability to make antibodies can affect response to vaccines. How well any one person responds to the COVID-19 vaccines is hard to predict, so everyone should still get vaccinated.
Other than relying on the protection provided by vaccines and prior infections, we did not previously have much to offer people following COVID-19 exposure. However, in May 2026, the FDA approved ensitrelvir, an oral postexposure prophylactic agent for adults and adolescents 12 years and older. In the SCORPIO-PEP trial, ensitrelvir significantly reduced the risk of developing COVID-19 among individuals who lived in a household with someone who was diagnosed with COVID-19. Overall, there was a 67% reduction in the risk of developing symptomatic COVID-19 and a 76% reduction among those with a condition that placed them at high risk for severe COVID-19.
Ensitrelvir does have interactions with other medications because it affects enzymes and transporters involved in the metabolism of other drugs. This could be significant for those who are older and with comorbidities, as these individuals are often on medications, some of which can interact with ensitrelvir. There are limited data on the effects of ensitrelvir in pregnant women, so I would caution against its use in this population because animal studies suggest fetal harm. Overall, when it comes to postexposure prophylaxis, it is important that clinicians check the package insert, use a drug interaction checker, and make educated decisions based on their patient’s individual needs.
Although COVID-19 appears to be here to stay, we have tools that we can use to help further reduce its ability to spread.
Hayden FG, Shinkai M, Clark TW, et al; SCORPIO-PEP Study Team. Ensitrelvir for Covid-19 postexposure prophylaxis in household contacts. N Engl J Med. 2026;394(19):1905-1915. doi:10.1056/NEJMoa2509306
la Cruz RAR, Flores-Córdova JM, Calderon-Hernandez CC, Cahuapaza-Gutierrez NL, Ccallalli-Ruiz NA, Runzer-Colmenares FM. Humoral and cellular immune responses against SARS-CoV-2 following COVID-19 vaccination in older adults: a systematic review. Vaccines (Basel). 2025;13(8):852. doi:10.3390/vaccines13080852
National Center for Health Statistics. Provisional percent of deaths for COVID-19, influenza, and RSV. Updated November 6, 2026. Accessed November 9, 2026. https://data.cdc.gov/Health-Statistics/Provisional-Percent-of-Deaths-for-COVID-19-Influen/4bc2-bbpq
Scott J, Abers MS, Marwah HK, et al. Updated evidence for Covid-19, RSV, and influenza vaccines for 2025-2026. N Engl J Med. 2025;393(22):2221-2242. doi:10.1056/NEJMsa2514268
Shimizu R, Matsuzaki T, Oka R, et al. Evaluation of drug-drug interactions of ensitrelvir, a SARS-CoV-2 3CL protease inhibitor, with transporter substrates based on in vitro and clinical studies. J Clin Pharmacol. 2023;63(8):918-927. doi:10.1002/jcph.2247
Shimizu R, Sonoyama T, Fukuhara T, et al. Evaluation of the drug-drug interaction potential of ensitrelvir fumaric acid with cytochrome P450 3A substrates in healthy Japanese adults. Clin Drug Investig. 2023;43(5):335-346. doi:10.1007/s40261-023-01265-8



